Please wait while the formulary information is being retrieved.
TRETINOIN (TRETINOIN)
- Acute promyelocytic leukemia
(chemotherapy) 10 mg capsule
- 22.5 mg/m2 by oral route 2 times per day
10 mg capsule
- 22.5 mg/m2 by oral route 2 times per day
Acute promyelocytic leukemia
- 22.5 mg/m2 by oral route 2 times per day
- Adoxa
- Avidoxy
- demeclocycline
- Doryx
- Doxy-100
- doxycycline calcium
- doxycycline hyclate
- doxycycline monohydrate
- Minocin
- minocycline
- Monodox
- Morgidox
- natalizumab
- Oracea
- Solodyn
- tetracycline
- tigecycline
- Tygacil
- Tysabri
- Vibramycin
Contraindicated
- Cyklokapron
- Lysteda
- tranexamic acid
Severe
Moderate
- None
- Lactating mother
- Pregnancy
Contraindicated
- Abnormal hepatic function tests
- Acute myocardial infarction
- Differentiation syndrome in acute promyelocytic leukemia
- Disease of liver
- Dyspnea
- Edema
- Fever
- Hemorrhage
- Hypercholesterolemia
- Hypertriglyceridemia
- Idiopathic intracranial hypertension
- Kidney disease with reduction in GFR
- Leukocytosis
- Pericardial effusion
- Pleural effusions
- Pulmonary infiltrates
- Venous thrombosis
Severe
Moderate
- None
TRETINOIN (TRETINOIN)
- Acute promyelocytic leukemia
- Abnormal hepatic function tests
- Acute respiratory insufficiency
- Cardiac arrhythmia
- Depression
- Differentiation syndrome in acute promyelocytic leukemia
- Earache
- Gastrointestinal hemorrhage
- Kidney disease with reduction in GFR
- Leukocytosis
- Ocular disorders
- Skin rash
- Stomatitis
- Acute abdominal pain
- Alopecia
- Anorexia
- Bone pain
- Chest discomfort
- Chills
- Constipation
- Diarrhea
- Dizziness
- Dry nose
- Dry skin
- Dyspnea
- Edema
- Fatigue
- Fever
- Flushing
- Headache disorder
- Hyperhidrosis
- Insomnia
- Malaise
- Myalgias
- Nausea
- Paresthesia
- Pruritus of skin
- Symptoms of anxiety
- Visual changes
- Vomiting
- Weight gain
- Xerostomia
More Frequent
Severe
Less Severe
- Acidosis
- Ascites
- Asthma
- Benign prostatic hyperplasia
- Cellulitis
- Cerebral edema
- Cerebrovascular accident
- Disseminated intravascular coagulation
- Dysuria
- Fluid volume disorder
- Gastrointestinal ulcer
- Hearing loss
- Heart failure
- Hemorrhage
- Hepatitis
- Hypertension
- Hypertriglyceridemia
- Hypotension
- Hypothermia
- Idiopathic intracranial hypertension
- Intracranial hypertension
- Laryngeal edema
- Phlebitis
- Pneumonia
- Pulmonary edema
- Pulmonary infiltrates
- Reduced visual acuity
- Renal failure
- Renal tubular necrosis
- Abdominal distension
- Acute confusion
- Agitation
- Agnosia
- Aphasia
- Drowsy
- Dyspepsia
- Flank pain
- Gait abnormality
- Hallucinations
- Hypercholesterolemia
- Increased urinary frequency
- Memory impairment
- Muscle weakness in limbs
- Pallor
- Rales
- Upper respiratory infection
- Weight loss
- Wheezing
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Acute renal failure
- Bone tenderness
- Coma
- Dementia
- Erythema nodosum
- Intracerebral hemorrhage
- Myocarditis
- Myositis
- Pericarditis
- Pleural effusions
- Pulmonary hypertension
- Seizure disorder
- Skin ulcer
- Splenomegaly
- Sweet's syndrome
- Thrombocytosis
- Thrombotic disorder
- Vasculitis
Less Severe
- Hypercalcemia
- Visual field defect
Contraindicated
None
Severe Precaution
Tretinoin (Oral)
Risk of pseudotumor cerebri. No safety and efficacy age < 1 year.
- 1 Day – 364 Days
- Risk of pseudotumor cerebri. No safety and efficacy age < 1 year.
Management or Monitoring Precaution
Tretinoin (Oral)
Risk of pseudotumor cerebri. Monitor for headache. Consider dose reduction for toxicity.
- 1 Years – 18 Years
- Risk of pseudotumor cerebri. Monitor for headache. Consider dose reduction for toxicity.
Tretinoin-oral
- Severity Level:
1
- Additional Notes: May be expected to cause fetal abnormality or death
Contraindicated
Tretinoin,oral
Mothers should discontinue nursing.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mothers should discontinue nursing. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Tretinoin may cause serious (sometimes fatal) side effects. Therefore, it must be used only under close medical supervision. Some patients may develop a life-threatening syndrome, usually during the first month of treatment with this medication.<br /><br />Tell your doctor right away if you experience any of the following symptoms: fever, trouble breathing, unusual tiredness, weight gain, swelling of the arms/legs/ankles/feet, dizziness, or fainting. You may be given other medications (including corticosteroids such as dexamethasone) to treat these side effects. Your doctor will also monitor your white blood cell count.<br /><br /> This medication can cause severe birth defects if used during pregnancy. Therefore, this medication is not recommended for use during pregnancy. Also, it is important to prevent pregnancy while taking this drug.<br /><br />Pregnancy tests should be done one week before you start treatment with tretinoin. When possible, do not start tretinoin treatment until you have a negative pregnancy test result. As soon as treatment begins, you must immediately start using two effective forms of birth control together (or completely avoid sexual intercourse).<br /><br />However, do not use "mini-pills" (progesterone birth control pills that do not contain estrogen) because they may not work as well while you are taking tretinoin. You must also have monthly pregnancy testing and birth control counseling from your doctor while taking this medication. Continue using birth control as directed until one month after tretinoin use has been stopped.
| Acute promyelocytic leukemia | |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| 0-9 | A-Z |
|---|---|
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
Formulary Reference Tool